Why Is IMMIX BIOPHARMA INC (IMMX) Stock Moving Today?
By the Top Tier Newswire AI Desk · July 20, 2026 at 12:30 PM ET · reviewed against 6 wire stories
IMMIX BIOPHARMA INC (IMMX) is drawing unusual attention today. Our newswire has captured 6 stories on IMMX across 5 sources in the last 36 hours, with AI sentiment reading bearish (avg 38/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Why IMMX stock is moving today
IMMX stock is moving lower today, down nearly 10% as of the latest trade at $9.01. The decline follows the arrest of Immix Biopharma’s chief medical officer and the termination of his employment, which has triggered investor concern and legal inquiries. The stock opened with a 4.0% gap down and has since traded in a volatile range between $8.73 and $10.05.
What Happened
Immix Biopharma shares fell sharply after the company filed an 8-K with the SEC disclosing the termination of its chief medical officer. The termination came in the wake of his arrest, which is being investigated for potential securities fraud. The Kehoe Law Firm has issued a notice encouraging investors to contact them regarding possible claims. The firm cited the arrest as a potential catalyst for investor losses. Meanwhile, a Benzinga article highlighted a STAT News piece that identified the former CMO as a fugitive previously wanted by law enforcement. The firm is also the subject of an ongoing analyst report that raises questions about product safety and adoption rates.
What The Data Shows
The stock is trading at $9.01, down from a 52-week high of $12.14. With a market cap of $729.7 million and a beta of 0.09, the stock has shown relatively low volatility historically. However, today’s session is unusually active, with 2.1 million shares traded, 1.6 times the 3-month daily average. The stock opened with a $9.84 price and has since fallen to a session low of $8.73. The intraday decline reflects heightened uncertainty among investors.
What To Watch
The company has not scheduled an earnings report in the near term. Investors should monitor the breadth of coverage and legal developments in the coming days, particularly as the Kehoe Law Firm and other legal entities assess potential claims.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
IMMX · Jul 20 session (5-min) · -14.39% vs prior close · updated 8:51 PM ETAI sentiment, last 36h · averaged over 6 stories · 38/100 bearish
The headlines behind the move
Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
32m agoMarketChameleonBEARISH 24General
Immix Biopharma prices 11.36 million-share offering at $11.00 to raise $125 million for NXC-201 development
September 29, 2026
Immix Biopharma (IMMX) announced the pricing of an underwritten offering of 11,363,637 common shares at $11.00 per share, with expected gross proceeds of $125 million. The company said it plans to use the net proceeds to fund NXC-201 development along with working capital and general corporate purposes, with the offering expected to close on or about September 30, 2026.
36m agoSeeking AlphaBEARISH 24General
Immix Biopharma prices $125M stock offering
Immix Biopharma (IMMX) prices 11.36M-share offering at $11 to raise $125M to fund NXC-201 development.
42m agoThe FlyBULLISH 76Product/PR
Immix announces 89% CR rate in interim update across NEXICART-2 patients
53m agoThe FlyBEARISH 24General
Immix Biopharma prices 11.36M share registered offering at $11.00
1h agoBusiness InsiderBEARISH 28General
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten...
IMMIX BIOPHARMA INC (IMMX) is drawing unusual attention today. Our newswire has captured 6 stories on IMMX across 5 sources in the last 36 hours, with AI sentiment reading bearish (avg 38/100). The most recent driver: "Immix Biopharma prices 11.36 million-share offering at $11.00 to raise $125 million for NXC-201 development
September 29, 2026" (MarketChameleon).
Is IMMX a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of IMMX coverage reads 38/100 over 6 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →